OPC - Oncology Pharmacists Connect

Eugene Przespolewski, PharmD, BCOP, DPLA, shares insights from his presentation at the 2025 OPC meeting in Austin, Texas.

Pharmacy experts share the benefits of the annual Oncology Pharmacists Connect meeting.

Kevin Chen, PharmD, MS, BCOP, CPP, highlighted key thoracic cancer advances from the 2025 ASCO Annual Meeting.

Scott Soefje, PharmD, MBA, BCOP, shares insights about the evolving role of pharmacists at the 2025 OPC meeting.

Gabe Hinojosa, PharmD, BCOP, shares key data for pharmacists from the 2025 American Society of Clinical Oncology Annual Meeting.

Oncology pharmacists are increasingly shaping patient care by integrating remote care, medication reconciliation, and artificial intelligence (AI), as well as by addressing drug shortages.

At the 2025 Oncology Pharmacists Connect (OPC) meeting, Kevin Chen, PharmD, MS, BCOP, CPP, reviewed several key studies from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting significant advancements in the treatment of small cell and non–small cell lung cancer.

Heidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment of cutaneous malignancies.

Jolynn Sessions, PharmD, BCOP, FHOPA, shares her experience as a clinical pharmacist and the value of the Oncology Pharmacists Connect meeting.

At the 2025 Oncology Pharmacists Connect (OPC) meeting, Courtney Cavalieri, PharmD, BCOP, presented clinical trial findings in gastrointestinal (GI) cancers—including colon, gastric, pancreatic, and metastatic colorectal cancer—that highlight the expanding role of immunotherapy and targeted treatments.

At the 2025 Oncology Pharmacists Connect (OPC) meeting, Mya Tran, PharmD, BCOP, highlights the clinical promise, operational challenges, and evolving role of pharmacists in implementing precision medicine and genomics-driven cancer care.

Victoria Nacher, PharmD, BCOP, offers key insights about the evolving treatment landscape for hematologic malignancies.

Tim Mok, PharmD, BCOP, BCPS, discusses emerging advancements in treatment of leukemia and lymphoma.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, co-chair of the 2025 Oncology Pharmacists Connect (OPC) meeting, discusses what makes the event unique, highlights key sessions, and shares her excitement for the educational and networking opportunities.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Heidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment for patients with cutaneous malignancies and melanoma.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, discusses the impact of CAR T cell and bispecific therapies in treatment of patients with hematological malignancies.

Rose DiMarco, PharmD, BCPS, BCOP, shares insights into the evolving treatment landscape for patients with breast cancer with specific mutations.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the crucial role pharmacists play in providing supportive care for patients with cancer.

Jordyn P. Higgins, PharmD, BCOP, discusses the evolving treatment landscape for small cell lung cancer (SCLC).

The quadruplet regimen added bortezomib to the current standard of care, which is a triplet regimen of isatuximab, lenalidomide, and dexamethasone for patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM TI).

There are numerous challenges with cell and gene therapies in oncology, such as accessibility, cost, and prior authorizations, as well as the need for improved education and training within the oncology community.